Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...
Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers for ...
Hosted on MSN2d
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
TipRanks on MSN2d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback